



ASX Release

11 May 2026

Acrux raises \$1.6 million through Share Placement

Melbourne, Australia; Acrux Limited (ASX:ACR)

Highlights:

- Acrux has received binding commitments totalling \$1.6 million under a Share Placement to institutional and professional investors at an issue price of 0.95 cents per share.
- Commitment bids totalling \$2.6 million were received and the Placement was scaled back by \$1.0 million.
- The Company proposes to offer 1 unlisted attaching option for every 2 shares subscribed for under the Placement (Attaching Options), to be issued subject to shareholder approval. Attaching Options will have an exercise price of \$0.018 and a 3 year term.

Overview

Acrux Limited (the **Company** or **Acrux**) is pleased to announce it has received and accepted binding commitments from new and existing institutional and professional investors to subscribe for new fully paid ordinary shares to raise \$1.6 million (before costs).

Proceeds from the Share Placement will be used to fund the Company's ongoing development of female testosterone and to support the company as it reaches a co-development agreement with an international partner.

John Warmbrunn, Acrux CEO and Managing Director, said:

"We are delighted in the support we have received from new and existing shareholders for the Placement. The level of excess commitments indicates a high level of interest in our Phase III clinical trials for Female Testosterone and the co-development pathway with an international partner. Acrux's know how and our existing commercialised portfolio mean we are very well placed to meet the growing, global, unmet need for women with hypoactive sexual desire dysfunction

We are grateful to our shareholders for their continued support."

Capital Raising

The \$1.6 million Placement has an offer price of 0.095 cents per new share, a 13.6% discount to the last traded price of \$0.0110 and a 16.8% discount to the 5 Day VWAP of \$0.0114 cents per share to 9 May 2026.

Attaching Options

Company proposes to offer Placement participants with one free Attaching Option for every two shares subscribed for under the Placement, subject to shareholder approval.

The Attaching Options will have an exercise price of 1.8 cents and expire 3 years after issuance. The offer of Attaching Options will be subject to shareholder approval at an Extraordinary General Meeting expected to be held in July 2026. Full details of the offer of the Attaching Options will be set out in the Notice of Extraordinary General Meeting.

Fees payable to Alpine Capital as Lead Managers include six Options for every share issued under the Placement, excluding shares issued to participants introduced by Acrux, to be issued on the same terms and at the same time as the Attaching Options to be issued to placement participants.

This announcement has been authorised for release to the ASX by the CEO and Managing Director of Acrux.

For more information, please contact:

John Warembrunn

CEO & Managing Director

E: john.warembrunn@acrux.com.au

Joanna Johnson

CFO & Company Secretary

E: joanna.johnson@acrux.com.au

P: + 61 3 8379 0100

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. For further information on Acrux, visit: www.acrux.com.au